The three parties will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest.
Under the deal, each company will bring distinct and valuable contributions to the collaboration, including the US provider and patient environment, research capabilities, therapeutics and methods expertise, and integrated, researchable data.
Lilly senior vice-president and chief medical officer Tim Garnett said: "Delivering high-quality outcomes for patients is a goal Lilly shares with Anthem and with all stakeholders in the healthcare system.
"The need has never been greater to translate an ever-increasing amount of complex data into targeted and meaningful information that enables better decision-making by patients, healthcare professionals and industry."
The collaboration allows the companies to explore research opportunities across disease states and incorporate surveys and other information from providers and patients.